Redeye comments on Oncopeptides’ Q1 report. Sales amounted to SEK25m, an increase by 37% versus Q4 2025. Italy surpassed expectations, Germany and Greece were in line, while Spain continues to lag due to the doctors' strike. Cost reductions resulted in operating expenses decreasing by SEK10m. With a strengthened cash position following the net SEK167m rights issue and a slightly lower cost structure, we estimate the company can achieve positive cash flow with a lower quarterly growth rate than before. We make some positive changes to our base case.
LÄS MER
